DNA RNA and Cells

02 Nov 2016 Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia
02 Nov 2016 Renova Therapeutics announces successful End-of-Phase 2 meeting with FDA for RT-100 AC6 gene transfer therapy
02 Nov 2016 DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA
01 Nov 2016 Bellicum and Ospedale Pediatrico Bambino Gesù Announce Expanded Collaboration to Develop Novel CAR T and TCR Cell Therapies Engineered with CaspaCIDe
01 Nov 2016 Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
28 Oct 2016 Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
26 Oct 2016 OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer
25 Oct 2016 AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis
24 Oct 2016 Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2
20 Oct 2016 Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy
20 Oct 2016 Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day
19 Oct 2016 The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si
18 Oct 2016 Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)
18 Oct 2016 Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
17 Oct 2016 Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic Response at Week 12 in Patients with Active Crohn’s Disease
15 Oct 2016 Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
13 Oct 2016 bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day
13 Oct 2016 OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer
12 Oct 2016 Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
11 Oct 2016 MeiraGTx Expands ALS Gene Therapy Program in Collaboration with Weill Cornell Medicine and LSU
11 Oct 2016 Agilis Biotherapeutics Announces Authorization of Phase IIb Clinical Study of Gene Therapy for AADC Deficiency
11 Oct 2016 Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord
11 Oct 2016 Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
11 Oct 2016 ZIOPHARM Presents Data Demonstrating Activation of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 in Patients with Advanced Breast Cancer
10 Oct 2016 Preclinical data presented at the European Society for Medical Oncology (ESMO) conference shows synergy of NOXXON’s lead compound NOX-A12 with both T-cell and NK cell based therapies

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top